These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10579685)

  • 1. Enterohepatic circulation model for population pharmacokinetic analysis.
    Funaki T
    J Pharm Pharmacol; 1999 Oct; 51(10):1143-8. PubMed ID: 10579685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetic model for the enterohepatic circulation of mycophenolic acid].
    Jiao Z; Shen J; Zhong LJ; Yu YQ; Zhong MK
    Yao Xue Xue Bao; 2006 Mar; 41(3):272-6. PubMed ID: 16759002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of mycophenolic acid in renal transplant recipients.
    van Hest RM; van Gelder T; Vulto AG; Mathot RA
    Clin Pharmacokinet; 2005; 44(10):1083-96. PubMed ID: 16176120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure.
    Okour M; Jacobson PA; Ahmed MA; Israni AK; Brundage RC
    J Clin Pharmacol; 2018 May; 58(5):628-639. PubMed ID: 29329489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.
    Colom H; Lloberas N; Andreu F; Caldés A; Torras J; Oppenheimer F; Sanchez-Plumed J; Gentil MA; Kuypers DR; Brunet M; Ekberg H; Grinyó JM
    Kidney Int; 2014 Jun; 85(6):1434-43. PubMed ID: 24402086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil.
    Prémaud A; Debord J; Rousseau A; Le Meur Y; Toupance O; Lebranchu Y; Hoizey G; Le Guellec C; Marquet P
    Clin Pharmacokinet; 2005; 44(8):837-47. PubMed ID: 16029068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.
    Sherwin CM; Sagcal-Gironella AC; Fukuda T; Brunner HI; Vinks AA
    Br J Clin Pharmacol; 2012 May; 73(5):727-40. PubMed ID: 22053944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease.
    Sherwin CM; Fukuda T; Brunner HI; Goebel J; Vinks AA
    Clin Pharmacokinet; 2011 Jan; 50(1):1-24. PubMed ID: 21142265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.
    Yau WP; Vathsala A; Lou HX; Zhou S; Chan E
    J Clin Pharmacol; 2009 Jun; 49(6):684-99. PubMed ID: 19386625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis.
    Czock D; Rasche FM; Carius A; Glander P; Budde K; Bauer S; Keller F; von Müller L
    J Clin Pharmacol; 2007 Jul; 47(7):850-9. PubMed ID: 17526858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S; Schoemaker R; Scholten E; den Hartigh J; König-Quartel J; van Kan E; Paul L; de Fijter J
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
    Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
    Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oral mycophenolate mofetil in dog: bioavailability studies and the impact of antibiotic therapy.
    Lupu M; McCune JS; Kuhr CS; Gooley T; Storb R
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1352-4. PubMed ID: 17162219
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.
    Abd Rahman AN; Tett SE; Abdul Gafor HA; McWhinney BC; Staatz CE
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):993-1004. PubMed ID: 28536776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function.
    Johnson HJ; Swan SK; Heim-Duthoy KL; Nicholls AJ; Tsina I; Tarnowski T
    Clin Pharmacol Ther; 1998 May; 63(5):512-8. PubMed ID: 9630824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients.
    Cattaneo D; Cortinovis M; Baldelli S; Bitto A; Gotti E; Remuzzi G; Perico N
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1147-55. PubMed ID: 17928466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mycophenolate mofetil, a new immunosuppressive agent. Is pharmacokinetic monitoring justified?].
    Barré J; Simon N; Tillement JP
    Therapie; 1997; 52(2):139-42. PubMed ID: 9231509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics of mycophenolic acid in Chinese patients with liver transplant].
    Yu ZC; Chen H; Zhang WX; Zhou PJ; Zhou GW; Chen HZ
    Yao Xue Xue Bao; 2006 Dec; 41(12):1157-60. PubMed ID: 17290612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome.
    Saint-Marcoux F; Guigonis V; Decramer S; Gandia P; Ranchin B; Parant F; Bessenay L; Libert F; Harambat J; Bouchet S; Broux F; Compagnon P; Marquet P
    Pharmacol Res; 2011 May; 63(5):423-31. PubMed ID: 21272643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.